As healthcare technology continues to evolve, the integration of devices, drugs, and data is becoming increasingly important. This year’s ARCS Annual Conference, held at the Sydney ICC, highlighted this confluence, underscoring a shift towards a more interconnected, personalised, and data-driven approach to healthcare delivery. This shift has the potential to revolutionise how diseases are prevented, diagnosed, and treated, ultimately leading to better patient outcomes and more efficient healthcare systems.
At the conference, our Executive Chairman, Saurabh Jain, had the distinct honour of presenting alongside Navid Toosi Saidy, PhD, in a discussion moderated by Carl Bufe, Director of PharmOut. The focus was on “Future-Proofing Medicine: AI’s Role in Predicting Clinical Trial Success.” During this session, we delved into how AI and Large Language Models (LLMs) are transforming pharmaceutical regulatory processes and enhancing clinical trial outcomes.
A common misconception about using AI in clinical trials is that it will replace human trials. In reality, AI supports clinical researchers and pharmaceutical companies by synthesising data faster and more accurately, eliminating the need for manual data encoding and analysis, and thereby streamlining the entire process.
The Role of AI in Clinical Trials
AI is playing a pivotal role in predicting clinical trial success and enhancing the way these trials are conducted. By leveraging AI, researchers can:
- Improve Data Analysis: AI can analyse vast amounts of data quickly and accurately, helping researchers identify patterns and insights that would be difficult to discern manually.
- Optimise Trial Design: AI tools can simulate various trial designs and predict their outcomes, allowing researchers to select the most effective protocols.
- Enhance Patient Selection: AI can refine inclusion and exclusion criteria, ensuring that the right patient population is chosen for each trial.
- Select Optimal Partners: AI can help identify the best countries, sites, principal investigators, CROs, and other collaborators based on historical data and predictive analytics.
These discussions align seamlessly with our mission at TrialKey. As we presented our solutions to a global audience of pharmaceutical companies, clinical research organizations, sponsors, and investors, it became evident that our AI-driven approach is precisely what the industry needs.
Introducing Trial Gen
At TrialKey, we have developed a clinical trial simulator called Trial Gen. This innovative tool employs cutting-edge AI technology, trained on real-world data from over 350,000 clinical trials. This extensive dataset enables Trial Gen to provide highly accurate and effective protocol designs tailored to the unique needs of each trial.
Trial Gen optimises crucial trial characteristics to ensure the best possible outcomes, including:
- Choice of Endpoints: Identifying the most relevant and impactful endpoints.
- Inclusion/Exclusion Criteria: Defining precise criteria to select the right patient population.
- Choice of Partners: Selecting optimal countries, sites, principal investigators, CROs, and other collaborators.
- Detailed Protocol Decisions: Making informed decisions on patient numbers, masking, trial arms, and intervention models.
- Real-World Constraints: Allowing users to select alternatives based on constraints such as patient levels related to budgets and observe how estimated success rates change.
The integration of AI in clinical trials represents a significant step towards future-proofing medicine. By enabling data-driven decisions and optimising trial designs, AI ensures that the healthcare industry adapts to the evolving world.
The discussions at the ARCS Annual Conference emphasised the transformative potential of AI, and our work at TrialKey with Trial Gen is a concrete example of how we are contributing to this evolution. As we move forward, the confluence of devices, drugs, and data will continue to shape the future of healthcare, driving improvements in patient outcomes and system efficiencies. AI will be at the forefront of this transformation, making it an essential tool in the future of medicine.
